2022 March Life Sciences Update

Even though NIH funding declined for the first time since 2014, 2021 funding—$33.5 billion— still outpaced pre-pandemic levels by 7.8%. It continues to be weighted towards the largest markets, with the top 10 markets accounting for half of all U.S. funding. In addition, PE funding increased by 29%, exceeding $44 billion, and PE and public offering investment in life sciences companies has been just over $86 billion since the pandemic began. Funding Remains Strong

3 / CUSHMAN & WAKEFIELD

LIFE SCIENCES 2022 MARCH UPDATE